Newton Charles W.
Insider CIK 1866219 · NVAX Director · CHRS Director · KROS Director · LYEL Chief Financial Officer · TSVT Director
Trades across companies
| Ticker | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|
| KROS Keros Therapeutics, Inc. | S Sale | 2026-08-18 | 2026-08-20 | 551 | $10.30 | $5.7K | 12,114 | SEC↗ |
| KROS Keros Therapeutics, Inc. | S Sale | 2026-08-18 | 2026-08-20 | 551 | $10.30 | $5.7K | 12,114 | SEC↗ |
| NVAX NOVAVAX INC | A Award deriv | 2026-06-18 | 2026-06-23 | 21,270 | — | $0 | 21,270 | SEC↗ |
| NVAX NOVAVAX INC | A Award deriv | 2026-06-18 | 2026-06-23 | 14,180 | — | $0 | 14,180 | SEC↗ |
| KROS Keros Therapeutics, Inc. | S Sale | 2026-06-11 | 2026-06-15 | 550 | $10.04 | $5.5K | 12,665 | SEC↗ |
| CHRS Coherus Oncology, Inc. | A Award deriv | 2026-06-05 | 2026-06-09 | 60,000 | — | $0 | 60,000 | SEC↗ |
| CHRS Coherus Oncology, Inc. | A Award | 2026-06-05 | 2026-06-09 | 30,000 | — | $0 | 30,000 | SEC↗ |
| NVAX NOVAVAX INC | M Exercise deriv | 2026-04-25 | 2026-04-28 | 9,520 | — | $0 | 19,040 | SEC↗ |
| NVAX NOVAVAX INC | M Exercise | 2026-04-25 | 2026-04-28 | 9,520 | — | $0 | 9,520 | SEC↗ |
| KROS Keros Therapeutics, Inc. | A Award deriv | 2026-03-09 | 2026-03-11 | 14,788 | — | $0 | 14,788 | SEC↗ |
| KROS Keros Therapeutics, Inc. | A Award | 2026-03-09 | 2026-03-11 | 13,215 | — | $0 | 13,215 | SEC↗ |
| LYEL Lyell Immunopharma, Inc. | S Sale | 2025-08-21 | 2025-08-22 | 1,453 | $10.54 | $15.3K | 15,306 | SEC↗ |
| LYEL Lyell Immunopharma, Inc. | A Award | 2025-08-20 | 2025-08-22 | 8,000 | — | $0 | 16,759 | SEC↗ |
| LYEL Lyell Immunopharma, Inc. | S Sale | 2025-08-12 | 2025-08-13 | 136 | $10.34 | $1.4K | 8,759 | SEC↗ |
| LYEL Lyell Immunopharma, Inc. | S Sale | 2025-08-11 | 2025-08-13 | 131 | $10.53 | $1.4K | 8,895 | SEC↗ |
| CHRS Coherus Oncology, Inc. | A Award deriv | 2025-06-12 | 2025-06-13 | 112,000 | — | $0 | 112,000 | SEC↗ |
| TSVT 2seventy bio, Inc. | D To issuer deriv | 2025-05-13 | 2025-05-15 | 33,400 | — | $0 | 0 | SEC↗ |
| TSVT 2seventy bio, Inc. | D To issuer deriv | 2025-05-13 | 2025-05-15 | 12,050 | — | $0 | 0 | SEC↗ |
| TSVT 2seventy bio, Inc. | D To issuer | 2025-05-13 | 2025-05-15 | 17,092 | — | $0 | 5,533 | SEC↗ |
| TSVT 2seventy bio, Inc. | U Tender | 2025-05-13 | 2025-05-15 | 5,533 | — | $0 | 0 | SEC↗ |
| NVAX NOVAVAX INC | A Award deriv | 2025-04-25 | 2025-04-29 | 42,840 | — | $0 | 42,840 | SEC↗ |
| NVAX NOVAVAX INC | A Award deriv | 2025-04-25 | 2025-04-29 | 28,560 | — | $0 | 28,560 | SEC↗ |
| LYEL Lyell Immunopharma, Inc. | P Buy | 2025-03-17 | 2025-03-18 | 200,000 | $0.56 | $112.0K | 200,000 | SEC↗ |
| LYEL Lyell Immunopharma, Inc. | A Award deriv | 2025-02-10 | 2025-02-26 | 56,250 | — | $0 | 56,250 | SEC↗ |
| LYEL Lyell Immunopharma, Inc. | A Award deriv | 2025-02-10 | 2025-02-26 | 450,000 | — | $0 | 450,000 | SEC↗ |
| LYEL Lyell Immunopharma, Inc. | A Award | 2025-02-10 | 2025-02-26 | 112,500 | — | $0 | 172,725 | SEC↗ |
| TSVT 2seventy bio, Inc. | A Award deriv | 2024-06-10 | 2024-06-12 | 12,050 | — | $0 | 12,050 | SEC↗ |
| TSVT 2seventy bio, Inc. | A Award | 2024-06-10 | 2024-06-12 | 6,025 | — | $0 | 22,625 | SEC↗ |
| CHRS Coherus BioSciences, Inc. | A Award deriv | 2024-06-03 | 2024-06-05 | 112,000 | — | $0 | 112,000 | SEC↗ |
| TSVT 2seventy bio, Inc. | A Award deriv | 2024-03-20 | 2024-03-25 | 33,400 | — | $0 | 33,400 | SEC↗ |
| TSVT 2seventy bio, Inc. | A Award | 2024-03-20 | 2024-03-25 | 16,600 | — | $0 | 16,600 | SEC↗ |
| LYEL Lyell Immunopharma, Inc. | A Award deriv | 2024-02-09 | 2024-02-13 | 400,000 | — | $0 | 400,000 | SEC↗ |
| LYEL Lyell Immunopharma, Inc. | A Award | 2024-02-09 | 2024-02-13 | 40,000 | — | $0 | 48,729 | SEC↗ |
| LYEL Lyell Immunopharma, Inc. | D To issuer deriv | 2023-11-16 | 2023-11-20 | 516,000 | — | $0 | 0 | SEC↗ |
| LYEL Lyell Immunopharma, Inc. | A Award deriv | 2023-11-16 | 2023-11-20 | 500,000 | — | $0 | 500,000 | SEC↗ |
| LYEL Lyell Immunopharma, Inc. | D To issuer deriv | 2023-11-16 | 2023-11-20 | 500,000 | — | $0 | 0 | SEC↗ |
| LYEL Lyell Immunopharma, Inc. | A Award deriv | 2023-11-16 | 2023-11-20 | 516,000 | — | $0 | 516,000 | SEC↗ |
| LYEL Lyell Immunopharma, Inc. | D To issuer deriv | 2023-11-16 | 2023-11-20 | 190,000 | — | $0 | 0 | SEC↗ |
| LYEL Lyell Immunopharma, Inc. | D To issuer deriv | 2023-11-16 | 2023-11-20 | 3,612,000 | — | $0 | 0 | SEC↗ |
| LYEL Lyell Immunopharma, Inc. | A Award deriv | 2023-11-16 | 2023-11-20 | 3,612,000 | — | $0 | 3,612,000 | SEC↗ |
| LYEL Lyell Immunopharma, Inc. | A Award deriv | 2023-11-16 | 2023-11-20 | 190,000 | — | $0 | 190,000 | SEC↗ |
| CHRS Coherus BioSciences, Inc. | A Award deriv | 2023-06-07 | 2023-06-09 | 38,250 | — | $0 | 38,250 | SEC↗ |
| LYEL Lyell Immunopharma, Inc. | A Award deriv | 2023-02-24 | 2023-02-28 | 700,000 | — | $0 | 700,000 | SEC↗ |
| CHRS Coherus BioSciences, Inc. | A Award deriv | 2022-05-04 | 2022-05-06 | 54,000 | — | $0 | 54,000 | SEC↗ |
| LYEL Lyell Immunopharma, Inc. | A Award deriv | 2022-03-16 | 2022-03-18 | 500,000 | — | $0 | 500,000 | SEC↗ |